Unseasonal showers hit Madrid during the European Society for Medical Oncology congress where most of the major data readouts came from the biggest players in the sector rather than ambitious biotechs. Here, In Vivo looks at three must-see presentations from the prestigious meeting.

The two firms will co-develop and co-commercialize three Daiichi ADCs globally outside Japan in a deal the Japanese firm said would allow “more aggressive development plans targeting broader patient populations.” 

Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.